{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:32:49Z","timestamp":1790519569988,"version":"4.1.0"},"reference-count":76,"publisher":"Informa UK Limited","issue":"18","funder":[{"name":"work was funded by a grant for the \u201cOverseas Famous Teachers\u201d"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2023,12,12]]},"DOI":"10.1080\/14656566.2023.2276180","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T09:13:12Z","timestamp":1698311592000},"page":"1937-1947","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6717-5444","authenticated-orcid":false,"given":"Brian","family":"Tomlinson","sequence":"first","affiliation":[{"name":"Macau University of Science and Technology","place":["Macau, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hong","family":"Li","sequence":"additional","affiliation":[{"name":"South China University of Technology","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2817-5"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00003-1"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1297424"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S009"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.05.028"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1307"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06715-0"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1672660"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-0074-6"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072761"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.10.1189"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1985465"},{"key":"e_1_3_5_17_1","unstructured":"U.S. Food and Drug Administration. Guidance for Industry. Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Dec 2008. Available from www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071627.pdf. Accessed 1 May 2023."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13648"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038868"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.09.009"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_3_5_34_1","unstructured":"FDA Approves Novel Dual-Targeted Treatment for Type 2 Diabetes. May 13 2022. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-dual-targeted-treatment-type-2-diabetes. Accessed 20 Jun 2023."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1736"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3039-1"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60683-2"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2762"},{"key":"e_1_3_5_40_1","volume-title":"INVOKAMET\u00ae XR (canagliflozin and metformin hydrochloride extended-release) tablets, for oral use [package insert]","year":"2016","unstructured":"INVOKAMET\u00ae XR (canagliflozin and metformin hydrochloride extended-release) tablets, for oral use [package insert]. Titusville: Janssen Pharmaceuticals; 2016. https:\/\/www.janssenlabels.com\/package-insert\/product-patient-information\/INVOKAMET+XR-medication-guide.pdf"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01517.x"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2391"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2113385"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15040442"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa023"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4345"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0434-2"},{"key":"e_1_3_5_48_1","first-page":"70","article-title":"Invokamet (canagliflozin plus metformin HCl): first fixed-dose combination with an SGLT2 inhibitor approved for the treatment of patients with type 2 diabetes","volume":"8","author":"Fala L","year":"2015","unstructured":"Fala L. Invokamet (canagliflozin plus metformin HCl): first fixed-dose combination with an SGLT2 inhibitor approved for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):70\u201374.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S69282"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0285-z"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.056440"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1541981"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.4172\/jbb.1000199"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202233"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016030278"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020122"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12273"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12322"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2491"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13115"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231190443"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108824"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13104"},{"issue":"2","key":"e_1_3_5_67_1","first-page":"225","article-title":"Dose comparison and side effect profile of metformin extended release versus metformin immediate release","volume":"29","author":"Hameed M","year":"2017","unstructured":"Hameed M, Khan K, Salman S, et al. Dose comparison and side effect profile of metformin extended release versus metformin immediate release. J Ayub Med Coll Abbottabad. 2017 Apr;29(2):225\u2013229.","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"e_1_3_5_68_1","unstructured":"FDA approves invokamet XR (canagliflozin\/metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes. Sep 21 2016. Available at: https:\/\/www.drugs.com\/newdrugs\/fda-approves-invokamet-xr-canagliflozin-metformin-hydrochloride-extended-release-adults-type-2-4433.html. Accessed 20 Jul 2023."},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht295"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.139816"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2017.01.005"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00975-y"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32131-2"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa956"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2023.2276180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T04:05:58Z","timestamp":1744689958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2023.2276180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":76,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,12,12]]}},"alternative-id":["10.1080\/14656566.2023.2276180"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2023.2276180","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}